NeuroDerm rises on Phase IIa PD readout, new EU path

NeuroDerm Ltd. (NASDAQ:NDRM) gained $6.15 to $29.30 on Wednesday after it said ND0612H met the primary endpoint in the Phase IIa Trial 006 to treat advanced Parkinson’s disease. The company also revealed a new European development plan for the high-dose levodopa/carbidopa liquid formulation, as well as low-dose version ND0612L. Both are delivered subcutaneously via a belt pump.

The 38 patients in Trial 006 received one of two 28-day dose regimens -- either a 24-hour cycle including a high day rate for 18 hours and a low night rate for 6 hours, or a morning dose followed by continuous administration for 14 waking hours...